FKBP Inhibitors

Featured Inhibitors
Inhibitors (4)
Modulators (2)
Activators (2)
Agonist (1)

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S8317	3BDO	3BDO, a butyrolactone derivative, could target FKBP1A and activate the mTOR signalling pathway. It inhibits autophagy in HUVECs. This compound inhibits oxLDL-induced apoptosis.	NPJ Parkinsons Dis, 2024, 10(1):52 Adv Sci (Weinh), 2023, 10(13):e2205436 Research Square, 2023, 10.21203/rs.3.rs-3629594/v1
S7091	Zotarolimus (ABT-578)	Zotarolimus (ABT-578, A 179578), an analogue of rapamycin, inhibits FKBP-12 binding with an IC50 of 2.8 nM.	Molecules, 2023, 28(6)2820 Molecules, 2023, 28(6), 2820 PLoS Biol, 2019, 17(5):e3000252

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S8317

3BDO

3BDO, a butyrolactone derivative, could target FKBP1A and activate the mTOR signalling pathway. It inhibits autophagy in HUVECs. This compound inhibits oxLDL-induced apoptosis.

NPJ Parkinsons Dis, 2024, 10(1):52

Adv Sci (Weinh), 2023, 10(13):e2205436

Research Square, 2023, 10.21203/rs.3.rs-3629594/v1

S7091

Zotarolimus (ABT-578)

Zotarolimus (ABT-578, A 179578), an analogue of rapamycin, inhibits FKBP-12 binding with an IC50 of 2.8 nM.

Molecules, 2023, 28(6)2820

Molecules, 2023, 28(6), 2820

PLoS Biol, 2019, 17(5):e3000252